

## Publication of patent application strengthens iZafe Group's grip on the digitalization of home care

**Stockholm, Sweden. iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) ("the company") reports that a patent application filed by the company has been published. The patent relates to a further development of the medication management robot Dosell, enabling Dosell and the Dosell app to become a hub for connected sensors and other digital care equipment in the home collection and measuring patient-specific data. The patent application is international and enables iZafe to have patents approved in more than 150 countries.**

The current patent application could provide the company with future patents in a large number of countries including Sweden, other parts of Europe and the USA. The fact that iZafe has a patent pending already in itself affords important protection for the company's further development of Dosell as a digital platform and additionally strengthens iZafe's position in the market.

*"The digitalization of healthcare has accelerated in recent years, and iZafe is a leading provider of medication dose dispensing for those who want to manage their medication themselves. By protecting the further development of Dosell into a digital hub for a future digital clinic in the home, we are strengthening our position as well as our patent portfolio,"* says Anders Segerström, CEO of iZafe Group.

The patent application relates to the development of a system for dispensing medication via the Dosell robot in which the dose of medication dispensed is adjusted based on current patient-specific information.

*"We are convinced that the ecosystem that Dosell provides via medication dispensing and the SaaS-based services is just the start of a rapid digitalization of many measurements that can be monitored by the doctor responsible for the patient via the Dosell app. The fact that we now have a patent pending in this area is an important part of our long-term strategy for positioning iZafe as a leading player in the digitalization of home and remote healthcare. Publication of the patent application that was filed 18 months ago strengthens our position in the market while also protecting us from competitors,"* says Anders Segerström.

### **Future digital care in the home**

We are living longer and longer, and an aging population increases the need for care and social services. Society aims to deliver increasing quality for our seniors and an important part of this ambition is to offer an increasing level of care in the home. iZafe's vision of a "digital clinic in the home" will only be possible if important information about the patient's state of health can be measured and communicated to the treating doctor.

This further development of Dosell allows sensors in the home to take the patient's readings and communicate these via iZafe's cloud-based solution. The treating doctor can then make sure that the correctly adjusted dose is always given to the patient via Dosell. The new technology further increases patient safety in respect of the dosing and dispensing of medication. Using Dosell as a hub

realizes the vision of a digital doctor's round in the home, which will be particularly important for patients being treated for conditions such as dementia, complex heart problems, diabetes, Parkinson's and MS.

*"Through Dosell, iZafe has already set a new standard for digital medication dispensing and future patents will enable the company to revolutionize care – above all in the home and especially for seniors, people with multiple conditions and patients on multiple medications,"* says Dr Göran Sjönell, doctor in general medical practice, co-founder of iZafe Group and inventor of Dosell.

## Contacts

---

Thomas Ahlerup, IR contact  
E-mail: [thomas.ahlerup@izafe.se](mailto:thomas.ahlerup@izafe.se)  
Phone number: +46 76-896 63 00

iZafe Group AB (publ)  
Grev Turegatan 11A  
114 46 Stockholm

E-mail: [ir@izafe.se](mailto:ir@izafe.se)  
[investor.izafe.se](mailto:investor.izafe.se)

## About Us

---

iZafe Group is a Swedish med-tech company that develops and markets medical and digital security solutions to create safer drug handling at home. Our digital medicine dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. Our products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: [info@fnca.se](mailto:info@fnca.se). Further information is available at [investor.izafe.se](http://investor.izafe.se).

## Attachments

---

[Publication of patent application strengthens iZafe Group's grip on the digitalization of home care](#)